Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2020 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter · In April, it was announced that the ongoing COVID-19 pandemic, resulted in a three month delay of Cantargia’s CANFOUR trial. · In May, the US Food and Drug Administration (FDA) approved Cantargia’s IND application from April for the start of clinical trials in the US with CAN04 and immunotherapy. · At the 2020 AACR Annual Meeting in June, new preclinical results

Interim report January – June 2020

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value fell to SEK 127 per share, compared with SEK 136 per share at the start of the year. This is a decrease of 5.5 per cent. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) decreased by 4.1 per cent. The net asset value was SEK 140 per share at 19 August. (1) · The total return on the Latour share was 11.5 per cent during the period measured against the SIXRX, which fell 4.1 per cent. INDUSTRIAL OPERATIONS The second quarter · The industrial operations' order intake fell 1 per cent to SEK 3,

Higher sales but lower profiability due to currency effects and increased costs

PowerCell Sweden AB increased its sales during the second quarter 2020 with 42 percent, from MSEK 15.5 to 22 due to continued large sales to Bosch and the order for a megawatt system we received from a leading European shipbuilder during the quarter. Operating income before items affecting comparability weakened to MSEK -28.3 (-16.7) due to, among other things, negative currency effects, lower gross margin, increased costs for selling and administration as well as for research and development. The Corona outbreak affected the activity level in China specifically but had no significant impact

Half-Year Report 1 January 2020 – 30 June 2020

Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes theHalf-Year Report for the period 1 January – 30 June 2020. The Half-Year Report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.Reporting period April 2020 – June 2020 · Net sales amounted to DKK 0 (0). · Operating profit was -4.75 m DKK (-4.85). · Cash and bank assets amounted to 7.28 m DKK (3.16). · Result per share was DKK -0.18 (-0.33). Reporting period January 2020 – June 2020 · Net sales amounted to DKK 0 (0). · Operating profit

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2020

Orphan Drug designation for MIV-818 in the EU and in USAApril – JuneSignificant events during the quarter · Following the positive opinion given by the European Medicines Agency (EMA), the European Commission granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer. · The Board of Directors appointed Yilmaz Mahshid as the new CEO of Medivir. Yilmaz Mahshid has long and broad experience from qualified roles in the life science sector. He will assume his position

Integrum AB appoints James Sheridan as Head of Sales and Marketing EMEA

Integrum, a leading provider of innovative solutions for bone anchored prosthetics, is proud to announce the appointment of James Sheridan as its Head of Sales and Marketing EMEA starting from September 1[st], 2020. As Head of Sales and Marketing, James Sheridan will be instrumental in leading Integrum´s sales and marketing team towards an accelerated expansion in EMEA. He comes to the role with more than 20 yearsof international experience working within Medical Devices in the Dental Implant Industry in markets like Australia, Japan and the Nordics. During his career he has gained

Serneke presents new business plan and announces Capital Markets Day

Serneke has set out a new business plan extending until 2025 and has adopted new long-term financial targets. The company will be holding an online Capital Markets Day on Tuesday, September 29 to present the new business plan and the strategic focus looking ahead.Having focused strongly on growth from the outset in 2002, Serneke is now conducting an extensive process on which to build the next phase in the company’s development. The new business plan sets out a clear strategy for how Serneke will focus on profitability, stability, and a continued strong corporate culture over the upcoming

Sharp deterioration in Viking Line’s results due to the impact of COVID-19

Viking Line Abp          Half-year Financial Report          20.08.2020    9.00 AM Sharp deterioration in Viking Line’s results due to the impact of COVID-19 January–June 2020 (compared to January–June 2019) · Sales amounted to EUR 97.5 M (227.0). · Other operating revenue was EUR 16.1 M (0.2). · Operating income totalled EUR -27.4 M (-8.8). · Net financial items were EUR -2.1 M (-2.2). · Income before taxes amounted to EUR -29.5 M (-11.0). · Income after taxes totalled EUR -23.7 M (-8.7). · Change in prospects: The impact of COVID-19 pandemic has continued to

RANPLAN WIRELESS

RANPLAN GROUP AB – Interim report January – June 2020 (Cision) 2020-08-20 08:00The period in summary• Total income amounted to SEK 12.2 million (30.6 million) 1• Operating results amounted to SEK -18.6 million (-1.6 million) 1• Net results amounted to SEK -20.2 million (-1.6 million) 1• Earnings per share amounted to SEK -1.01 (-0.08) 1• Cash at the end of the period amounted to SEK 10.8 million (5.1 million) 11 All comparisons are made to the first half of 2019, the numbers of which have been subject to adjustments as detailed in the Annual Report for 2019. Total income

Quarterly Report Q2-2020: First participant in the hepatic study

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2-2020 (April – June 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q2-2020 · First participant enrolled in the clinical hepatic impairment study with Mangoral · Directed share issue to partly fund preparations for Mangoral market launch · Patent for Oncoral approved in Japan SIGNIFICANT EVENTS AFTER THE PERIOD · Proceeds from directed share issue received in the beginning of July FINANCIAL SUMMARY

Dignitana AB Publishes Q2 2020 Interim Report

Dignitana holds steady during challenging marketFinancial highlights · Group revenue in Q2 2020 amounted to 11 876 TSEK (12 002 TSEK), a decrease of 1 percent over the same period in 2019 and a decrease of 5 percent over Q1 2020. · EBITDA in Q2 2020 amounted to -5 066 TSEK (-5 165 TSEK), an improvement of 2 percent over the same period in 2019 and an improvement of 42 percent compared to Q1 2020. · Earnings per share in Q2 2020 is -0.17 SEK compared to -0,16 SEK in the same period 2019. · Average Daily Treatment Revenue (ADTR)* was 126 TSEK (99 TSEK), an increase of 27 percent

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during the second exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or the “Company”) today announces that the second period to subscribe for shares in the Company by exercise of warrants (ticker CTM TO1) (the “Warrants) commences today, 20 August 2020.The second period to subscribe for shares in the Company by exercise of Warrants commences today, 20 August 2020, and runs up to and including 29 August 2020. During this period, each Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 18.90. Payment of subscribed shares can

Humana reports second quarter and half-year 2020 results

A quarter with continued focus on minimising the effects of the pandemicSecond quarter, April-June 2020 · Operating revenue was SEK 1,980 million (1,918), an increase of 3%. Organic growth was 3.4%. · Operating profit was SEK 100m (45), an increase of 123%. Capital gain of SEK 17m from sale of properties is included. Adjusted operating profit was SEK 83m (45), an increase of 84%. · Net profit after tax for the period amounted to SEK 50m (-2). · Earnings per share for the period before and after dilution amounted to SEK 0.94 (-0.04). · Operating cash flow amounted to SEK

Optomed’s January–June 2020 Half Year Report to be published on Thursday 27 August 2020

Optomed Plc        Press Release       20 August 2020 at 9.00, Helsinki Optomed’s January–June 2020 Half Year Report to be published on Thursday 27 August 2020 Optomed will publish its January–June 2020 Half Year Report on Thursday 27 August 2020 approximately at 9.00 EEST. A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EEST. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EEST at the latest. The participants are requested to register for the call in advance

Interim Report January–June 2020

Growth outside Lidingö In early May, John Mattson took possession of the acquired apartments in Rotebro and Rotsunda in the municipality of Sollentuna. Plans to upgrade the apartments are now being developed in parallel with tangible measures carried out to improve well-being and safety in the area. In May, the company signed agreements to acquire three leasehold properties in Slakthusområdet in the City of Stockholm, with completion set for July. With these acquisitions, the company is back in the City of Stockholm and established in three municipalities in the Stockholm region. “

ISAB repositions its Contract Research business and launches “Inhalation Research Services” as new brand name

(Stockholm, 20 August 2020) Inhalation Sciences AB (ISAB) is repositioning its Contract Research business and launching it under a new brand name - Inhalation Research Services (IRS). IRS offers a comprehensive service portfolio that delivers precise and predictive early-stage respiratory research data. IRS has seen a steady increase in demand from its biopharma customers and has grown considerably during the Covid-19 pandemic.ISAB is organizing its operations into three business areas: The first is the sales of its PreciseInhale[® ]system and modules, the second is IRS, providing contract

ExpreS2ion – Half-year report for 2020 published

Hørsholm, Denmark, August 20, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's half-year report for 2020 is published. The half-year report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “Arguably, we just went through the most eventful quarter in our company’s 10-year history. Most importantly, we announced a manufacturing agreement with AGC Biologics, a licensing deal between AdaptVac and Bavarian Nordic, and not least, very promising animal data

Q2 Report 2020 – invitation to conference call and audiocast

On Thursday August 27, at 16.00 CET, IRRAS will host a conference call and an online presentation of its Q2 2020 interim report (which will have been published earlier on the 27[th] at 08.00 CET). The presentation will be held in English. The dial-in numbers for the conference call are:Sweden: +46 8 50 55 83 52Rest of the world: +44 33 33 00 92 67 The presentation will be webcast and can be accessed from the following web address:https://tv.streamfabriken.com/irras-q2-2020 Speakers: CEO Kleanthis G. Xanthopoulos, Ph.D., President and CCO Will Martin and CFO Sabina Berlin

Interim report

January 1 – June 30, 2020The second quarter in figures · Net sales amounted to TSEK 1,683 (2,168). · The loss after tax amounted to TSEK 8,864 (10,613). · The loss per share amounted to SEK 0.38 (0.64). · The cash flow from current operations was negative in the amount of TSEK 8,704 (9,900). · The gross margin reached 55.7% (53.3%). · Electrode sales volume decreased by 18% and reached 4,672 (5,712) units. Repeat sales of electrodes to existing customers decreased by 22%. The first half-year in figures · Net sales amounted to TSEK 4,179 (4,536). · The loss

Stille AB: Interim Report Q2 2020

Stille AB (publ) publishes report for the first half of and second quarter of 2020. “Positive tendencies in an otherwise tough quarter”, summarizes CEO Hanna Ernestam Wilkman.Revenue in the second quarter was negatively affected by COVID-19 and decreased by 20.4 percent compared to the same quarter previous year. Revenue amounted to 29.3 MSEK (36.8). The operating profit decreased to -1.5 MSEK (5.1) and was negatively impacted by items affecting comparability of 5.4 MSEK following depreciation of stock and a weakened US dollar. Simultaneously, the operating profit was positively impacted by

Interim report January-June 2020

HISTORICALLY STRONG ORDER BACKLOGApril - June 2020 · Order bookings amounted to SEK 1,851 million (2,663) · Income amounted to SEK 1,393 million (1,616) · The operating loss amounted to SEK 139 million (0), affected by non-recurring costs amounting to SEK 145 million · Cash flow from operating activities amounted to an outflow of SEK 156 million (302) · Cash flow for the period amounted to an outflow of SEK 38 million (210) · The loss for the period amounted to SEK 114 million (2) · The reorganization process is progressing and the effects of this are expected to

ZICCUM AB interim report January 1-June 30, 2020

Summary of the interim report - second quarter 2020 During the second quarter the company carried out a private placement of a total of 2,216,815 shares to a limited number of qualified private investors. The company received SEK 38.8 million before issue costs and approximately SEK 36.4 million after issue costs (of which approximately SEK 32.3 million was added during the second quarter and the remaining approximately SEK 6.5 million was added during July 2020). During the second quarter, the company received a loan from Almi Företagspartner Skåne AB amounting to SEK 2.0 million.April-

Interim report for January-June 2020

Active governance and risk reduction limit the effects from Covid-19 Second quarter 2020 (second quarter 2019) · Total revenue amounted to SEK 49.5 million (50.5), a decrease of 2 percent compared to the corresponding period last year. · EBITDA amounted to SEK 2.0 million (3.4) · The EBITDA margin amounted to 4.0 percent (6.6) · Operating profit (EBIT) amounted to SEK -0.9 million (1.2) · The EBIT margin amounted to -1.9 percent (2.3) · Result before tax amounted to SEK -2.5 million (0.8) · Cash flow amounted to SEK 6.0 million (0.5) · Average number of

Notice convening the Extraordinary General Meeting of SAS AB

Shareholders in SAS AB (publ) (hereinafter the “Company”) are hereby invited to attend the Extraordinary General Meeting on Tuesday 22 September 2020. The Extraordinary General Meeting will be held at 10:00 a.m. at the Company’s Head Office, Frösundaviks allé 1, Solna, Sweden. The meeting venue will open at 9:15 a.m. for registration. Registration of participants at the meeting ends when the meeting is called to order. SAS welcomes all shareholders to exercise their voting rights at the Extraordinary General Meeting through advance voting as described below. Information on the

There are no items matching the current filter
There are no more items matching the current filter
Back to top